• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Lexaria Bioscience Corp (NQ: LEXX )

    3.310 +0.010 (+0.30%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 88,178
    Open 3.320
    Bid (Size) 3.130 (1)
    Ask (Size) 3.500 (24)
    Prev. Close 3.300
    Today's Range 3.170 - 3.392
    52wk Range 0.8500 - 6.850
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Continues to Strengthen Executive Team in Anticipation of ‘Strong Growth’ into 2025
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Lexaria Appoints Michael Shankman as Chief Financial Officer
    Via ACCESSWIRE

    Performance

    YTD
    +156.59%
    +156.59%
    1 Month
    -9.32%
    -9.32%
    3 Month
    +25.38%
    +25.38%
    6 Month
    -2.93%
    -2.93%
    1 Year
    +231.00%
    +231.00%

    More News

    Read More
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Begin Human Pilot Study #3 Evaluating DehydraTECH-Processed Tirzepatide
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Begin Human Pilot Study #3 Evaluating DehydraTECH-Processed Tirzepatide
    Via CannabisNewsWire
    Topics Intellectual Property
    Exposures Intellectual Property
    Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3
    Via ACCESSWIRE
    Lexaria Welcomes Industry Veteran as New CEO
    Via ACCESSWIRE
    First Results from Lexaria's Second GLP-1 Human Pilot Study
    Via ACCESSWIRE
    TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating ‘More Effective, Tolerable’ Oral Delivery of GLP-1 Drugs
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires New CEO Amid Shift in Focus to Pharmaceutical Industry Collaboration and Operations
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires New CEO Amid Shift in Focus to Pharmaceutical Industry Collaboration and Operations
    Via CannabisNewsWire
    Topics Intellectual Property
    Exposures Intellectual Property
    Lexaria Bioscience Corp. (NASDAQ: LEXX) Demonstrates Continued DehydraTECH(TM)-Liraglutide Performance with Ongoing GLP-1 Diabetes Animal Study
    Via Investor Brand Network
    TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Market Potential with Unique Delivery Platform, GLP-1 Program
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Shares Letter from Outgoing CEO
    Via CannabisNewsWire
    Topics Intellectual Property
    Exposures Intellectual Property
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Shares Letter from Outgoing CEO
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints Medical Device and Pharmaceutical Industries Veteran as New CEO
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Lexaria Bioscience Corp. (NASDAQ: LEXX) Yields “Extremely Interesting” Results for DehydraTECH(TM) Liraglutide in Ongoing Diabetes Animal Study
    Via Investor Brand Network
    Lexaria Releases Strategic Letter from the Outgoing CEO
    Via ACCESSWIRE
    TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Material Transfer Agreement to Evaluate DehydraTECH(TM) Technology in Pre-Clinical Setting
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Lexaria Enters a Material Transfer Agreement for DehydraTECH Research
    Via ACCESSWIRE
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Additional Tolerability, PK Test Results
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules
    Via ACCESSWIRE
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces First Results from Second GLP-1 Human Pilot Study ‘Reinforcing DehydraTECH’s Beneficial Delivery Kinetics’
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces First Results from Second GLP-1 Human Pilot Study ‘Reinforcing DehydraTECH’s Beneficial Delivery Kinetics’
    Via CannabisNewsWire
    Topics Intellectual Property
    Exposures Intellectual Property
    Lexaria Bioscience Corp. (NASDAQ: LEXX) Validates Technology’s Superiority, Moving Closer to a Share in the Global Diabetes Treatment Market
    Via Investor Brand Network
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.